Full Breakdown
Lawsuits Filed Against New Jersey Genetic-Testing Companies Over IVF Misrepresentation
4/14/2026, 3:39:14 AM
Overview of the Lawsuits
Two New Jersey genetic-testing companies, Genomic Prediction and CooperGenomics, are facing class action lawsuits from patients undergoing in vitro fertilization (IVF). The lawsuits allege that these companies misrepresented the accuracy and effectiveness of a genetic test known as Preimplantation Genetic Testing for Aneuploidy (PGT-A), which is intended to screen embryos for chromosomal abnormalities. Plaintiffs claim that misleading marketing led to the wrongful discarding of viable embryos, significantly impacting their IVF outcomes.
Allegations of Misleading Marketing
The lawsuits assert that Genomic Prediction and CooperGenomics marketed PGT-A with claims of 98-99% accuracy, which the plaintiffs argue are not supported by scientific research. Attorney Allison Freeman, representing the plaintiffs, stated that the companies have been aware for years that their tests are less accurate than advertised. The complaints highlight that patients, influenced by these claims, made critical decisions regarding their embryos, including discarding those that may have been viable.
Patient Experiences
Maureen Ewing, a plaintiff in the lawsuit against Genomic Prediction, shared her personal experience, stating that she destroyed embryos based on PGT-A results that indicated abnormalities. She expressed regret, reflecting on the potential outcomes had she not relied on the test's results. Freeman emphasized that the emotional toll on patients is significant, describing the experience as "heartbreaking" for many who seek successful family planning through IVF.
Official Responses from the Companies
In response to the allegations, a spokesperson for Genomic Prediction stated that the company is dedicated to providing accurate, evidence-based information about its products and services. They emphasized their commitment to scientific rigor and patient care but noted that they could not comment further due to the ongoing legal proceedings. As of now, CooperGenomics has not publicly responded to the lawsuits.
Broader Implications
The lawsuits not only seek damages from the companies but also raise questions about the ethical marketing practices within the genetic testing industry. The outcomes of these cases could have significant implications for how genetic tests are marketed and the standards of evidence required to support such claims. With hundreds of thousands of women undergoing IVF annually, the repercussions of these lawsuits may extend beyond the immediate parties involved.
Conflicting Reports & Gaps
While the lawsuits claim that the companies have misled patients, the exact accuracy rates of PGT-A tests remain a point of contention. The plaintiffs allege that the accuracy is significantly lower than advertised, while the companies maintain their commitment to scientific integrity. The discrepancy in these claims highlights the need for clearer regulations and standards in the genetic testing field.
What's Next
Both lawsuits are currently seeking damages and a jury trial, with further developments expected as the legal proceedings unfold. The outcomes may influence future practices in the genetic testing industry and the broader IVF landscape.
